EP3302539A4 - Manufacturing multi-dose injection ready dendritic cell vaccines - Google Patents

Manufacturing multi-dose injection ready dendritic cell vaccines Download PDF

Info

Publication number
EP3302539A4
EP3302539A4 EP16800434.9A EP16800434A EP3302539A4 EP 3302539 A4 EP3302539 A4 EP 3302539A4 EP 16800434 A EP16800434 A EP 16800434A EP 3302539 A4 EP3302539 A4 EP 3302539A4
Authority
EP
European Patent Office
Prior art keywords
dendritic cell
cell vaccines
dose injection
manufacturing multi
injection ready
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16800434.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3302539A1 (en
Inventor
Brian J. Czerniecki
Gary K. Koski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/041022 external-priority patent/WO2016011422A2/en
Application filed by Individual filed Critical Individual
Publication of EP3302539A1 publication Critical patent/EP3302539A1/en
Publication of EP3302539A4 publication Critical patent/EP3302539A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP16800434.9A 2015-05-22 2016-03-05 Manufacturing multi-dose injection ready dendritic cell vaccines Withdrawn EP3302539A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165445P 2015-05-22 2015-05-22
PCT/US2015/041022 WO2016011422A2 (en) 2014-07-17 2015-07-17 Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
PCT/US2016/021090 WO2016190940A1 (en) 2015-05-22 2016-03-05 Manufacturing multi-dose injection ready dendritic cell vaccines

Publications (2)

Publication Number Publication Date
EP3302539A1 EP3302539A1 (en) 2018-04-11
EP3302539A4 true EP3302539A4 (en) 2018-12-19

Family

ID=57393543

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16800434.9A Withdrawn EP3302539A4 (en) 2015-05-22 2016-03-05 Manufacturing multi-dose injection ready dendritic cell vaccines

Country Status (5)

Country Link
EP (1) EP3302539A4 (zh)
JP (2) JP2018515421A (zh)
CN (1) CN107206061A (zh)
CA (1) CA2986687A1 (zh)
WO (1) WO2016190940A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109365A (zh) * 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
JPWO2019103151A1 (ja) * 2017-11-27 2021-01-21 国立大学法人千葉大学 核酸を細胞内に送達するための脂質膜構造体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846538A (en) * 1993-03-17 1998-12-08 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
WO2015139003A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian, J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
WO2016011347A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Multi-dose injection ready dendritic cell vaccines and combination therapy for cancer
WO2016153761A1 (en) * 2015-03-13 2016-09-29 Czerniecki Brian J Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
WO2016154508A1 (en) * 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping
WO2016154625A1 (en) * 2015-03-26 2016-09-29 Czerniecki Brian J In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US8247227B2 (en) * 2006-08-28 2012-08-21 The Cleveland Clinic Foundation Dendritic cell precursors
CN102933228A (zh) * 2010-03-15 2013-02-13 宾夕法尼亚大学董事会 制备和储存活化的、成熟树突细胞的体系和方法
KR20210052587A (ko) * 2010-12-30 2021-05-10 안트로제네시스 코포레이션 세포의 동결보존 및 캡슐화 방법
EP2548571A1 (en) * 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846538A (en) * 1993-03-17 1998-12-08 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
WO2015139003A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian, J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
WO2016011347A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Multi-dose injection ready dendritic cell vaccines and combination therapy for cancer
WO2016153761A1 (en) * 2015-03-13 2016-09-29 Czerniecki Brian J Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
WO2016154508A1 (en) * 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping
WO2016154625A1 (en) * 2015-03-26 2016-09-29 Czerniecki Brian J In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. J. CZERNIECKI ET AL: "Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion", CANCER RESEARCH, vol. 67, no. 4, 15 February 2007 (2007-02-15), & 102ND ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); ORLANDO, FL, USA; APRIL 02 -06, 2011, pages 1842 - 1852, XP055269484, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-4038 *
LEA LOWENFELD ET AL: "Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 pos DCIS Independent of Route: Results of Randomized Selection Design Trial", CLINICAL CANCER RESEARCH, vol. 23, no. 12, 15 June 2017 (2017-06-15), US, pages 2961 - 2971, XP055521767, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-1924 *
MITTENDORF E A: "HER-2 Pulsed Dendritic Cell Vaccine Can Eliminate HER-2 Expression and Impact Ductal Carcinoma In Situ Sharma A, Koldovsky U, Xu S, et al (Rena Rowan Breast Ctr, Philadelphia, PA; et al)Cancer118:4354-4362, 2012$", BREAST DISEASES: A YEAR BOOK QUARTERLY, MOSBY, ST. LOUIS, MO, US, vol. 24, no. 1, 15 March 2013 (2013-03-15), pages 55 - 56, XP029001806, ISSN: 1043-321X, DOI: 10.1016/J.BREASTDIS.2013.01.029 *
See also references of WO2016190940A1 *

Also Published As

Publication number Publication date
JP2018515421A (ja) 2018-06-14
WO2016190940A1 (en) 2016-12-01
CA2986687A1 (en) 2016-12-01
CN107206061A (zh) 2017-09-26
EP3302539A1 (en) 2018-04-11
JP2020180139A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
EP3322015A4 (en) Battery
EP3134131A4 (en) Nucleic acid vaccines
EP3121886A4 (en) Fuel cell, fuel cell manufacturing device
EP3145017A4 (en) Fuel cell
EP3201783A4 (en) Https request enrichment
EP3378933A4 (en) PROCESS FOR PREPARING CELL
EP3154110A4 (en) Electrode manufacturing method
EP3324470A4 (en) Fuel cell
HK1257438A1 (zh) 用生產免疫調節劑的免疫-分離的細胞接種疫苗
EP3132487A4 (en) Electrolyte formulations
GB201521284D0 (en) Fuel cell
EP3281660A4 (en) INJEKTOR
EP3207578A4 (en) Batteries
KR101882091B1 (ko) 캐비티를 갖는 폴리머-기반 반도체 구조체
EP3251707A4 (en) Infusion set
EP3249730A4 (en) Redox-flow battery
EP3187215A4 (en) Needless injector
EP3132120A4 (en) Scale identifier
EP3319157A4 (en) Fuel cell
EP3386618A4 (en) ULTRAVARIABLE ADVANCED MANUFACTURING TECHNIQUES
GB201601503D0 (en) Dendritic cells
AU2015225914B2 (en) Microneedle based cell delivery
EP3348292A4 (en) ASSEMBLY FOR INFUSION
EP3155180A4 (en) Pole arrangement
EP3549590A4 (en) CELL PREPARATION

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CZERNIECKI, BRIAN J.

Inventor name: KOSKI, GARY K.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181119

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/14 20150101ALI20181113BHEP

Ipc: A61K 39/00 20060101AFI20181113BHEP

Ipc: C07K 2/00 20060101ALI20181113BHEP

Ipc: A61K 35/12 20150101ALI20181113BHEP

Ipc: A61K 35/28 20150101ALI20181113BHEP

Ipc: C07K 1/00 20060101ALI20181113BHEP

Ipc: A61K 39/385 20060101ALI20181113BHEP

Ipc: C12N 5/00 20060101ALI20181113BHEP

Ipc: A61K 39/395 20060101ALI20181113BHEP

Ipc: C07K 14/00 20060101ALI20181113BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191024

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20210208BHEP

Ipc: C12N 5/0784 20100101ALI20210208BHEP

Ipc: C07K 1/00 20060101ALI20210208BHEP

Ipc: C07K 16/32 20060101ALI20210208BHEP

Ipc: A61K 35/17 20150101ALI20210208BHEP

Ipc: C07K 2/00 20060101ALI20210208BHEP

Ipc: C07K 14/00 20060101ALI20210208BHEP

Ipc: A61P 43/00 20060101ALI20210208BHEP

Ipc: A61K 35/12 20150101ALI20210208BHEP

Ipc: A61K 35/28 20150101ALI20210208BHEP

Ipc: A61K 39/385 20060101ALI20210208BHEP

Ipc: C12N 5/00 20060101ALI20210208BHEP

Ipc: A61P 35/00 20060101ALI20210208BHEP

Ipc: A61K 39/00 20060101AFI20210208BHEP

Ipc: A61K 35/14 20150101ALI20210208BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210730